直径不大于5 cm孤立性肝癌：射频消融与手术治疗的比较

doi:10.3969/j.issn.1009-976X.2022.04.003

岭南现代临床外科 ›› 2022, Vol. 22 ›› Issue (04): 328-335.DOI: 10.3969/j.issn.1009-976X.2022.04.003

直径不大于5 cm孤立性肝癌：射频消融与手术治疗的比较

张桥^1,2, 莫阿里^1,2, 高恒毅³, 周伟⁴, 夏丰⁵, 张伟桥^1,2, 陈伟强^1,2

1.广东医科大学,广东湛江 524023;
2.中山大学附属中山医院肝胆外科,广东中山528403;
3.深圳市龙华区人民医院肝胆外科,广东深圳 518109;
4.孝感中心医院肝胆外科,湖北孝感 432099;
5.华中科技大学附属同济医院肝脏外科,武汉 430030

通讯作者: *陈伟强,Email：cwq20138@aliyun.com

Comparison of survival outcomes between radiofrequency ablation and surgery for solitary hepatocellular carcinoma ≤ 5 cm （multicenter prognostic analysis）

ZHANG Qiao^1,2, MO A-li^1,2, GAO Heng-yi³, ZHOU Wei⁴, Xia Feng⁵, ZHANG Wei-liao^1,2, CHEN Wei-qiang^1,2

1. Guangdong Medical University, Zhanjiang, Guangdong 524023, China;
2. Department of Hepatobiliary Surgery, Zhongshan Hospital, Zhongshan University, Zhongshan, Guangdong 528403, China;
3. Department of Hepatobiliary Surgery, Shenzhen Longhua District People's Hospital, Shenzhen, Guangdong 518109, China;
4. Department of Hepatobiliary Surgery, Xiaogan Central Hospital, Xiaogan, Hubei 432099, China;
5. Department of Liver Surgery, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China

Received:2022-03-07 Online:2022-08-20 Published:2022-09-22
Contact: CHEN Wei-qiang, cwq20138@aliyun.com

摘要/Abstract

摘要： 目的分析射频消融（RFA）和手术切除（SR）两种治疗方式对直径≤5 cm孤立性肝细胞癌预后的影响,比较其优劣性。方法回顾性分析2015年1月至2018年12月中山大学附属中山医院、华中科技大学附属同济医院、孝感市中心医院收治的直径≤5 cm的孤立性肝细胞癌、并接受以上其中一种治疗方式的病人资料,共606例。患者分为A组（直径≤2 cm）、B组（2 cm<直径≤3 cm）、C组（3 cm<直径≤5 cm）3个亚组,其中A组：77例;B组：239例;C组：290例。调查RFA和SR两种治疗方式在各亚组和总体人群中对预后影响,并进一步分析影响RFA疗效的主要原因。结果在肝细胞癌患者总体人群中,行SR组患者的生存预后优于RFA组,差异具有统计学差异（P<0.05）。肿瘤直径≤2 cm时,SR与RFA临床疗效相当,生存预后和无复发生存无统计学差异（P>0.05）。2 cm<直径≤3 cm时,SR的生存预后和无复发生存均优于RFA;直径为>3 cm且≤5 cm的肝细胞癌患者,SR的生存预后和无复发生存优于RFA,差异存在统计学差异（P<0.05）。结论对于肿瘤直径≤2 cm患者,RFA可达到与SR一样的临床疗效;对于2 cm<肿瘤直径≤5 cm肝细胞癌患者,应优先考虑SR。

关键词: 肝细胞癌, 手术切除, 射频消融, 生存预后, 无肿瘤复发

Abstract: Objective To compare the effects of radiofrequency ablation （RFA） and surgical resection （SR） on the prognosis of solitary hepatocellular carcinoma with tumor diameter ≤5 cm. Method Theclinicopathological data of patients with solitary hepatocellular carcinoma with a diameter of ≤5 cm who were admitted to Zhongshan Hospital Affiliated to Sun Yat-sen University, Tongji Hospital Affiliated to Huazhong University of Science and Technology, and Xiaogan Central Hospital from January 2015 to December 2018 and who received the above two treatments were collected. A total of 606 cases were included in this study. According to tumor diameter, the patients were divided into three subgroups:Group A （diameter≤2 cm）, Group B （2 cm<diameter≤3 cm）, Group C （3 cm<diameter≤5 cm）, among which Group A:77 patients; Group B:239 patients; Group C:290 patients. The effects of RFA and SR on the prognosis in each subgroup and the total population were compared and analyzed, and the main reasons affecting the efficacy of RFA were further explored. Results In the overall population of patients, the survival prognosis of patients in the SR group was better than that in the RFA group, and the difference was statistically significant （P<0.05）. When the tumor diameter was less than or equal to 2 cm, the clinical efficacy of SR and RFA were comparable, and there was no significant difference in overall survival （OS） and recurrence-free survival （RFS）（P>0.05）. When 2 cm<diameter≤3 cm, SR had better OS and RFS than RFA; for patients with HCC whose tumor diameter was >3cm and ≤5 cm, SR had better long-term prognosis and RFS than RFA, the difference was statistically significant （P<0.05）. Conclusion For patients with tumor diameter ≤2 cm, RFA can achieve the same clinical efficacy as SR; for patients with of 2 cm<tumor diameter ≤5 cm, SR should be given priority.

Key words: hepatocellular carcinoma, surgical resection, radiofrequency ablation, overall survival, recurrence-free survival

中图分类号:

张桥, 莫阿里, 高恒毅, 周伟, 夏丰, 张伟桥, 陈伟强. 直径不大于5 cm孤立性肝癌：射频消融与手术治疗的比较[J]. 岭南现代临床外科, 2022, 22(04): 328-335.

ZHANG Qiao, MO A-li, GAO Heng-yi, ZHOU Wei, Xia Feng, ZHANG Wei-liao, CHEN Wei-qiang. Comparison of survival outcomes between radiofrequency ablation and surgery for solitary hepatocellular carcinoma ≤ 5 cm （multicenter prognostic analysis）[J]. Lingnan Modern Clinics In Surgery, 2022, 22(04): 328-335.

参考文献

[1] Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1):7.
[2] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[3] Yang JD, Heimbach JK.New advances in the diagnosis and management of hepatocellular carcinoma[J]. BMJ, 2020, 371:m3544.
[4] von Felden J, Garcia-Lezana T, Schulze K, et al. Liquid biopsy in the clinical management of hepatocellular carcinoma[J]. Gut, 2020, 69(11):2025-2034.
[5] 孙文兵. 射频消融在肝细胞癌综合治疗中的作用[J]. 中华肝胆外科杂志, 2015, 21(9):591-595.
[6] Cucchetti A, Piscaglia F, Cescon M, et al.Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma[J]. J Hepatol, 2013, 59(2):300-307.
[7] Forner A, Reig M, Bruix J.Hepatocellular carcinoma[J]. The Lancet, 2018, 391(10127):1301-1314.
[8] Peng ZW, Lin XJ, Zhang YJ, et al.Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller:a retrospective comparative study[J]. Radiology, 2012, 262(3):1022-1033.
[9] 陈敏山,李锦清,梁惠宏,等.经皮射频消融与手术切除治疗小肝癌的疗效比较[J].中华医学杂志,2005, (2):12-15.
[10] Lafaro K, Grandhi MS, Herman JM, et al.The importance of surgical margins in primary malignancies of the liver[J]. J Surg Oncol, 2016, 113(3):296-303.
[11] Makuuchi M.Remodeling the surgical approach to hepatocellular carcinoma[J]. Hepatogastroenterology, 2002, 49(43):36-40.
[12] Shi M, Guo RP, Lin XJ, et al.Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma:a prospective randomized trial[J]. Ann Surg, 2007, 245(1):36-43.
[13] Zhou XD, Tang ZY, Yang BH, et al.Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma[J]. Cancer, 2001, 91(8):1479-1486.
[14] Llovet JM, Kelley RK, Villanueva A, et al.Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1):6.
[15] Omata M, Cheng AL, Kokudo N, et al.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma:a 2017 update[J]. Hepatol Int, 2017, 11(4):317-370.
[16] Nault JC, Sutter O, Nahon P, et al.Percutaneous treatment of hepatocellular carcinoma:State of the art and innovations[J]. J Hepatol, 2018, 68(4):783-797.
[17] Lee SH, Jin YJ, Lee JW.Survival benefit of radiofrequency ablation for solitary (3-5 cm) hepatocellular carcinoma:An analysis for nationwide cancer registry[J]. Medicine (Baltimore), 2017, 96(44):e8486.
[18] Guglielmi A, Ruzzenente A, Valdegamberi A, et al.Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis[J]. J Gastrointest Surg, 2008, 12(1):192-198.
[19] Vivarelli M, Guglielmi A, Ruzzenente A, et al.Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver[J]. Ann Surg, 2004, 240(1):102-107.
[20] Heimbach JK, Kulik LM, Finn RS, et al.AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67(1):358-380.
[21] Livraghi T, Lazzaroni S, Meloni F.Radiofrequency thermal ablation of hepatocellular carcinoma[J]. Eur J Ultrasound, 2001, 13(2):159-166.
[22] 高航, 翁山耕, 张翔等.小肝癌合并微血管侵犯的术前危险因素分析及预测模型构建[J]. 中华普通外科杂志, 2019, 34(11):921-924.
[23] Iguchi T, Shirabe K, Aishima S, et al.New pathologic stratification of microvascular invasion in hepatocellular carcinoma:predicting prognosis after living-donor liver transplantation[J]. Transplantation, 2015, 99(6):1236-1242.
[24] Shi M, Zhang CQ, Zhang YQ, et al.Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin[J]. World J Surg, 2004, 28(4):376-381.

直径不大于5 cm孤立性肝癌：射频消融与手术治疗的比较

Comparison of survival outcomes between radiofrequency ablation and surgery for solitary hepatocellular carcinoma ≤ 5 cm （multicenter prognostic analysis）

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	蔡上林, 王博, 李坚. 吲哚菁绿荧光显影导航技术在肝胆外科手术中的应用进展[J]. 岭南现代临床外科, 2022, 22(04): 315-321.
[2]	龙吟, 宋兴东, 张磊. 中晚期肝癌转化治疗中的几个焦点问题[J]. 岭南现代临床外科, 2022, 22(02): 115-119.
[3]	马晓武, 谭文亮, 杨磊, 谢智钦, 王庆斌, 陈亚进, 商昌珍. 环状RNA circKDM4B调控肝癌细胞增殖及侵袭迁移的实验研究[J]. 岭南现代临床外科, 2021, 21(06): 614-619.
[4]	鲁旭, 李华, 易述红, 赵辉, 朱曙光, 李海波, 杨扬, 汪国营. 介入联合仑伐替尼桥接治疗超米兰标准肝癌肝移植2例报道[J]. 岭南现代临床外科, 2021, 21(05): 507-511.
[5]	王道笃, 赵其炯, 周志标, 何永越. 基于铁死亡相关基因构建肝细胞癌的预后模型[J]. 岭南现代临床外科, 2021, 21(04): 419-424.
[6]	丁陈陈, 宋兴东, 张磊. 肝脏外科医生眼中的2021 ASCO[J]. 岭南现代临床外科, 2021, 21(03): 265-271.
[7]	涂星强, 杜国能, 徐礼笑子, 许永辉, 肖玉根. 大隐静脉曲张术后复发因素的随访初析[J]. 岭南现代临床外科, 2021, 21(02): 195-199.
[8]	胡志鹏, 孙强, 胡泽民, 陈伟强. 基于增强CT的影像组学模型对BCLC B期肝细胞癌治疗方式选择的研究进展[J]. 岭南现代临床外科, 2021, 21(02): 233-238.
[9]	张弋, 李强, 赵斌. CT和腹腔镜引导下射频消融术治疗膈顶部复发性小肝癌的疗效分析[J]. 岭南现代临床外科, 2020, 20(04): 444-447.
[10]	陈景森，欧希，赵洋，余光银，刘晓平*. LAP+CD4+T细胞在肝癌微环境中的分布特点及意义[J]. 岭南现代临床外科, 2019, 19(05): 528-532.
[11]	蔡育志1，廖海华1，韩靖2，高剑1，刘丁一1，张彤1*. BORIS蛋白表达在胃癌中的表达及其预后价值[J]. 岭南现代临床外科, 2019, 19(03): 260-263.
[12]	潘景升，欧冰，王浩虎，林骅杰，杨晓微. 氩氦刀冷冻消融与射频消融在肝癌治疗中的临床应用[J]. 岭南现代临床外科, 2018, 18(06): 624-626.
[13]	刘旭臣陈剑萍 . 单纯等离子射频消融术与等离子射频消融结合臭氧技术治疗腰椎间盘突出症的疗效分析[J]. 岭南现代临床外科, 2017, 17(06): 733-736.
[14]	卢杰任慧青. 肝癌的多模式治疗[J]. 岭南现代临床外科, 2017, 17(06): 747-750.
[15]	陈洽铭韦金星李晓辉. 基因NEK9在肝细胞癌组织中的表达效应及其临床意义[J]. 岭南现代临床外科, 2017, 17(03): 267-270.